ABCL Stock Analysis: Abcellera Biologics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.403m USD | 12M Return: 90.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.3M
Qual. Beats: 2
Rev. Trend: -12.5%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 5.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AbCellera Biologics Inc. (ABCL) is a Vancouver-based biotechnology company that discovers and develops antibody-based medicines targeting indications with unmet medical need, primarily in the United States. Its pipeline includes ABCL635, a non-hormonal therapy in Phase 2 trials for moderate-to-severe vasomotor symptoms, and ABCL575, a half-life extended monoclonal antibody in Phase 1 development for T-cell-mediated autoimmune conditions such as atopic dermatitis. The company operates a partnership-driven business model, with research collaborations and license agreements with Eli Lilly, AbbVie, Biogen, and other investors, suggesting a reliance on milestone payments, royalties, and licensing revenue typical of clinical-stage biotech firms. Founded in 2012 and listed on NASDAQ since December 2020, AbCellera is classified within the Health Care sector under the Biotechnology sub-industry.
- ABCL635 Phase 2 vasomotor symptom trial data readout approaches
- Partnership milestones with Eli Lilly AbbVie Biogen drive royalty revenue
- Cash burn rate and runway shape capital allocation and dilution risk
| Net Income: -144.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA -3.86 > 1.0 |
| NWC/Revenue: 779.4% < 20% (prev 2.98k%; Δ -2.20k% < -1%) |
| CFO/TA -0.12 > 3% & CFO -153.3m > Net Income -144.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (303.1m) vs 12m ago 1.81% < -2% |
| Gross Margin: 63.61% > 18% (prev -474.2%; Δ 537.8% > 0.5%) |
| Asset Turnover: 5.97% > 50% (prev 1.72%; Δ 4.26% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.47 (Total Current Assets 664.6m - Total Current Liabilities 47.3m) / Total Assets 1.31b |
| B: -0.06 (Retained Earnings -72.6m / Total Assets 1.31b) |
| C: -0.14 (EBIT TTM -188.5m / Avg Total Assets 1.33b) |
| D: 2.54 (Book Value of Equity 938.1m / Total Liabilities 369.0m) |
| Altman-Z'' = 4.63 = AA |
| DSRI: 0.27 (Receivables 115.7m/126.6m, Revenue 79.2m/23.1m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.97 (AQ_t 0.17 / AQ_t-1 0.17) |
| SGI: 3.43 (Revenue 79.2m / 23.1m) |
| TATA: 0.01 (NI -144.0m - CFO -153.3m) / TA 1.31b) |
| Beneish M = -1.90 (Cap -4..+1) = B |
As of July 08, 2026, the stock is trading at USD 7.69 with a total of 8,041,630 shares traded. Over the past week, the price has changed by -5.30%, over one month by +41.88%, over three months by +133.03% and over the past year by +90.82%.
Current recommended Stop Loss: 6.90 (which is 10.3% or 1.3 ATR below the current price).
Abcellera Biologics has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy ABCL.
- StrongBuy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10.4 | 35.6% |
P/E Forward = 27.5482
P/S = 30.3417
P/B = 2.6401
Revenue TTM = 79.2m USD
EBIT TTM = -188.5m USD
EBITDA TTM = -157.6m USD
Long Term Debt = 134.3m USD (estimated: total debt 140.2m - short term 5.87m)
Short Term Debt = 5.87m USD (from shortTermDebt, last quarter)
Debt = 140.2m USD (from shortLongTermDebtTotal, last quarter) (leases 140.2m already included)
Net Debt = -364.6m USD (calculated: Debt 140.2m - CCE 504.7m)
Enterprise Value = 2.04b USD (2.40b + Debt 140.2m - CCE 504.7m)
Interest Coverage Ratio = unknown (Ebit TTM -188.5m / Interest Expense TTM 0.0)
EV/FCF = -10.77x (Enterprise Value 2.04b / FCF TTM -189.2m)
FCF Yield = -9.28% (FCF TTM -189.2m / Enterprise Value 2.04b)
FCF Margin = -238.9% (FCF TTM -189.2m / Revenue TTM 79.2m)
Net Margin = -181.7% (Net Income TTM -144.0m / Revenue TTM 79.2m)
Gross Margin = 63.61% ((Revenue TTM 79.2m - Cost of Revenue TTM 28.8m) / Revenue TTM)
Gross Margin QoQ = -4.09% (prev 82.34%)
Tobins Q-Ratio = 1.56 (Enterprise Value 2.04b / Total Assets 1.31b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 140.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -148.9m (EBIT -188.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.05 (Total Current Assets 664.6m / Total Current Liabilities 47.3m)
Debt / Equity = 0.15 (Debt 140.2m / totalStockholderEquity, last quarter 938.1m)
Debt / EBITDA = 2.31 (negative EBITDA) (Net Debt -364.6m / EBITDA -157.6m)
Debt / FCF = 1.93 (negative FCF - burning cash) (Net Debt -364.6m / FCF TTM -189.2m)
Total Stockholder Equity = 969.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.86% (Net Income -144.0m / Total Assets 1.31b)
RoE = -14.86% (Net Income TTM -144.0m / Total Stockholder Equity 969.0m)
RoCE = -17.08% (EBIT -188.5m / Capital Employed (Equity 969.0m + L.T.Debt 134.3m))
RoIC = -11.80% (negative operating profit) (NOPAT -148.9m / Invested Capital 1.26b)
WACC = 13.75% (E(2.40b)/V(2.54b) * Re(14.55%) + D(140.2m)/V(2.54b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 14.55% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 1.83%
[DCF] Fair Price = unknown (Cash Flow -189.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.22 | # QB: 2
Revenue Correlation: -12.53 | Revenue CAGR: -7.04% | SUE: 0.17 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.17 | Chg30d=+2.94% | Revisions=+40% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.17 | Chg30d=+0.96% | Revisions=+40% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.65 | Chg30d=+1.22% | Revisions=+57% | GrowthEPS=-32.6% | GrowthRev=-57.4%
EPS next Year (2027-12-31): EPS=-0.72 | Chg30d=+8.08% | Revisions=+40% | GrowthEPS=-10.8% | GrowthRev=-3.4%
[Analyst] Revisions Ratio: +77% (up=10, down=0)